Clinical trial · Observational
Methylation Patterns of the NUPR1, MGMT, NDRG2, and GLI1 Genes and Their Impact on Therapeutic Outcome of GBM Patients
Studying Some Epigenetic Modifications In Glioblastoma Multiforme and Their Impact On Clinical Outcome
NCT06538428CI-TRIAL-00079461completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aimed to investigate the role of promoter methylation of MGMT, NUPR1, NDRG2, and GLI1 genes in glioblastoma multiforme (GBM) patients. Tissue samples were collected from GBM patients and individuals with non-neurooncological diseases (NND). The methylation status of the four genes was analyzed, and the clinical characteristics and survival of GBM patients were evaluated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| GBM | Glioblastoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DNA methylation profiling | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- GBM group
- description
- 58 primary GBM treatment-naïve Egyptian patients DNA methylation profiling for four genes (MGMT, NUPR1,NDRG2,and GLI1 gene) using EpiTect Methyl II (qPCR) system (Qiagen, Germany).
- interventionNames
- Genetic: DNA methylation profiling
- label
- NND group
- description
- DNA methylation profiling for four genes (MGMT, NUPR1,NDRG2,and GLI1 gene) using EpiTect Methyl II (qPCR) system (Qiagen, Germany).
- interventionNames
- Genetic: DNA methylation profiling
Primary outcomes (1)
- measure
- GBM prognosis
- timeFrame
- two years
- description
- Determine the prognostic and predictive significance of the DNA methylation patterns of the examined genes in Egyptian GBM patients. Using the EpiTect Methyl II PCR Kit, The methylation levels of four genes: MGMT, NUPR1, NDRG2, and GLI1 were measured. Then, using Spearman correlation, their levels were correlated with GBM progression and therapeutic response to the chemotherapeutic drug \[temozolomide\].
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (age \> 18 years) * Recent diagnosis of GBM * Performance status of less than or equal to 2 on the Ester Clinical Oncology Group * (ECOG) scale,1) * Pathologically proven GBM Exclusion Criteria: * Other types of cancer, * HBV * HCV * Schistosomiasis * HCC * HIV * Alcohol intake * Thyroid dysfunction * Inflammatory diseases * Cerebrovascular disorders
References
Publications (0)
Data not yet available
No reference posted for this study.